SecBot SecBot
SECBOTREPLAY Home › Report › RYTM

RYTM · Rhythm Pharmaceuticals reported strong fourth quarter and full year…

RHYTHM PHARMACEUTICALS, INC. · 8-K filed Feb 26, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

8-K filed Feb 26, 2026 at 07:30 ET

Rhythm Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, with Q4 net product revenue of $57.3 million, representing 12% sequential growth and 37% year-over-year growth. The company also highlighted key clinical progress, including a positive end-of-Phase-2 meeting with the FDA for bivamelagon and upcoming PDUFA decision for setmelanotide in acquired hypothalamic obesity on March 20, 2026. Cash position increased to $388.9 million, providing funding for at least 24 months.

  • Q4 2025 net product revenue was $57.3 million, up 12% sequentially and 37% year-over-year from $41.8 million in Q4 2024
  • Full year 2025 revenue was $194.8 million, up 50% from $130.1 million in 2024
  • Net loss attributable to common stockholders was $48.8 million in Q4 2025, improved from $44.6 million in Q4 2024
  • Cash, cash equivalents and short-term investments were $388.9 million as of December 31, 2025, up from $320.6 million as of December 31, 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access